Foresite Capital Management III’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-108,630
| Closed | -$18.7M | – | 8 |
|
|
2021
Q3 | $18.7M | Hold |
108,630
| – | – | 25.92% | 2 |
|
|
2021
Q2 | $13.6M | Hold |
108,630
| – | – | 14.45% | 3 |
|
|
2021
Q1 | $14.7M | Hold |
108,630
| – | – | 12.94% | 2 |
|
|
2020
Q4 | $13.9M | Hold |
108,630
| – | – | 16.15% | 2 |
|
|
2020
Q3 | $12.2M | Buy |
108,630
+66,600
| +158% | +$6.63M | 9.1% | 4 |
|
|
2020
Q2 | $4M | Hold |
42,030
| – | – | 3.56% | 7 |
|
|
2020
Q1 | $3.78M | Sell |
42,030
-212,893
| -84% | -$16.5M | 6.01% | 7 |
|
|
2019
Q4 | $13.5M | Hold |
254,923
| – | – | 7.57% | 6 |
|
|
2019
Q3 | $10.1M | Hold |
254,923
| – | – | 3.85% | 9 |
|
|
2019
Q2 | $10.5M | Hold |
254,923
| – | – | 3.43% | 13 |
|
|
2019
Q1 | $11.9M | Buy |
254,923
+19,055
| +8% | +$837K | 3.09% | 12 |
|
|
2018
Q4 | $10.3M | Sell |
235,868
-14,995
| -6% | -$749K | 3.37% | 10 |
|
|
2018
Q3 | $14.4M | Sell |
250,863
-27,890
| -10% | -$1.37M | 3.17% | 9 |
|
|
2018
Q2 | $13.5M | Hold |
278,753
| – | – | 2.91% | 10 |
|
|
2018
Q1 | $10.9M | Hold |
278,753
| – | – | 2.38% | 13 |
|
|
2017
Q4 | $11.8M | Hold |
278,753
| – | – | 3.32% | 10 |
|
|
2017
Q3 | $10.4M | Buy |
278,753
+258,867
| +1,302% | +$8.99M | 2.87% | 10 |
|
|
2017
Q2 | $604K | Hold |
19,886
| – | – | 0.2% | 24 |
|
|
2017
Q1 | $526K | Hold |
19,886
| – | – | 0.2% | 25 |
|
|
2016
Q4 | $507K | Buy |
+19,886
| New | +$630K | 0.22% | 19 |
|
|
2016
Q2 | – | Sell |
-94,403
| Closed | -$2.49M | – | 25 |
|
|
2016
Q1 | $2.49M | Buy |
94,403
+44,356
| +89% | +$1.29M | 1.93% | 16 |
|
|
2015
Q4 | $2.44M | Buy |
+50,047
| New | +$1.8M | 2.16% | 15 |
|
Foresite Capital Management III's XLRN Position: Q4 2021 in Review
Foresite Capital Management III sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 108,630 shares — an estimated $18.7M sold.
Foresite Capital Management III first reported a position in XLRN in Q4 2015 and held it in 22 quarters. The position peaked at $18.7M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Foresite Capital Management III reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Foresite Capital Management III sold 108,630 Acceleron Pharma shares in Q4 2021, an estimated $18.7M.
- Foresite Capital Management III first reported a position in Acceleron Pharma in Q4 2015 and held it in 22 quarters.
- Foresite Capital Management III's Acceleron Pharma position peaked at $18.7M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Foresite Capital Management III's 13F filing for Q4 2021, filed 11 Feb 2022.